Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus ...
Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present data at the SNO/ASCO CNS Metastases Conference from August 14-16, 2025, in Baltimore, MD. The presentations will ...
CNSide® may catalyze LM treatment initiation, allow physicians to adapt treatment with real time shifts in tumor biology, and enable personalized cancer therapy HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results